Skip to Main Content

Author Details

Elena Ivanova
Dana-Farber Cancer Institute
2003
50
37
PMIDPaper TitleJournal TitlePublished Year
36634707Targeting TBK1 to overcome resistance to cancer immunotherapy.Nature2023
37627156Development of a Patient-Derived 3D Immuno-Oncology Platform to Potentiate Immunotherapy Responses in Ascites-Derived Circulating Tumor Cells.Cancers (Basel)2023
36634707Targeting TBK1 to overcome resistance to cancer immunotherapy.Nature2023
37384411Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer.J Clin Invest2023
37627156Development of a Patient-Derived 3D Immuno-Oncology Platform to Potentiate Immunotherapy Responses in Ascites-Derived Circulating Tumor Cells.Cancers (Basel)2023
37384411Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer.J Clin Invest2023
34548332EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.Cancer Res2022
35678717Activation of Tumor-Cell STING Primes NK-Cell Therapy.Cancer Immunol Res2022
34548332EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.Cancer Res2022
34887522Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.Br J Cancer2022
35678717Activation of Tumor-Cell STING Primes NK-Cell Therapy.Cancer Immunol Res2022
34887522Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.Br J Cancer2022
33151910Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade.J Clin Invest2021
33978307Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.Oncologist2021
33151910Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade.J Clin Invest2021
34516823Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of <i>EGFR</i>-mutant lung cancer.Sci Transl Med2021
34516823Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of <i>EGFR</i>-mutant lung cancer.Sci Transl Med2021
33978307Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.Oncologist2021
33013881Tumor-Derived cGAMP Regulates Activation of the Vasculature.Front Immunol2020
32034078Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non-Small Cell Lung Cancer.Clin Cancer Res2020
33013881Tumor-Derived cGAMP Regulates Activation of the Vasculature.Front Immunol2020
32034078Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non-Small Cell Lung Cancer.Clin Cancer Res2020
30633907Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.Cell2019
30297358Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.Cancer Discov2019
30633907Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.Cell2019
31331945The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.Cancer Immunol Res2019
31331945The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.Cancer Immunol Res2019
30297358Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.Cancer Discov2019
29101162<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.Cancer Discov2018
30072474Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-Small Cell Lung Cancer.Clin Cancer Res2018
30388456Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.Cell2018
30087114BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in <i>Kras</i>-Mutant Non-Small Cell Lung Cancer.Cancer Immunol Res2018
301837893D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade.Lab Chip2018
29101163CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.Cancer Discov2018
29101162<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.Cancer Discov2018
301837893D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade.Lab Chip2018
30072474Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-Small Cell Lung Cancer.Clin Cancer Res2018
30087114BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in <i>Kras</i>-Mutant Non-Small Cell Lung Cancer.Cancer Immunol Res2018
30388456Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.Cell2018
29101163CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.Cancer Discov2018
27573169Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.Clin Cancer Res2017
28351582Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck.Oral Oncol2017
27573169Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.Clin Cancer Res2017
27789775Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.Oncologist2017
28351582Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck.Oral Oncol2017
27789775Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.Oncologist2017
27539742Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment.Sci Rep2016
27856426Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.Cancer Immunol Res2016
27699239Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.JCI Insight2016
27539742Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment.Sci Rep2016
  • 1 - 50 of 100

Recommended Authors

Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 0
Tuo Zhang
Weill Cornell Medical College.
Career Start Year 2013
Number of shared co-authors 1
Daniel J McGrail
Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Career Start Year 2012
Number of shared co-authors 6
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Chad V Pecot
University of North Carolina at Chapel Hill
Career Start Year 2009
Number of shared co-authors 5
John T Poirier
Laura and Isaac Perlmutter Cancer Center
Career Start Year 2007
Number of shared co-authors 6
Pichai Raman
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year 2006
Number of shared co-authors 9
Linghua Wang
The University of Texas M. D. Anderson
Career Start Year 2006
Number of shared co-authors 15
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 3
Jesse S Boehm
Broad Institute of Harvard and MIT
Career Start Year 2004
Number of shared co-authors 24
Kristopher K Frese
Cancer Research UK Manchester Institute, University of Manchester
Career Start Year 2003
Number of shared co-authors 0
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 1
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 15
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 1
Andrew V Kossenkov
The Wistar Institute
Career Start Year 2003
Number of shared co-authors 6
Donghui Cheng
University of California los angeles
Career Start Year 2003
Number of shared co-authors 0
Trever G Bivona
University of California san francisco
Career Start Year 2002
Number of shared co-authors 7
Habib Hamidi
Genentech Inc.
Career Start Year 2002
Number of shared co-authors 0
Wenyan Zhong
Oncology R&D
Career Start Year 2000
Number of shared co-authors 0
Nhu-An Pham
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1998
Number of shared co-authors 2
Lianbo Yu
The Ohio State University
Career Start Year 1997
Number of shared co-authors 1
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 21
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 3
Michael Peyton
Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center
Career Start Year 1994
Number of shared co-authors 8
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 33
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 3
Charles M Rudin
Memorial Sloan Kettering Cancer Center
Career Start Year 1989
Number of shared co-authors 9
Lori S Hart
Children's Hospital of Philadelphia, USA. [2] Center for Childhood Cancer Research
Career Start Year 1987
Number of shared co-authors 5
Daniel S Peeper
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 6

Collaborators

Alexei Protopopov
The University of MD Anderson Cancer Center
Co-authored papers 14
Pasi A J??nne
Dana-Farber Cancer Institute
Co-authored papers 11
Lynda Chin
Co-authored papers 11
Yonghong Xiao
TESARO Inc.
Co-authored papers 7
Peter S Hammerman
Novartis Institutes for BioMedical Research
Co-authored papers 7
Raphael Bueno
Co-authored papers 6
Andrew Portell
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute
Co-authored papers 6
Yaoqi Alan Wang
The University of Texas MD Anderson Cancer Center
Co-authored papers 6
Robert T Jones
Co-authored papers 5
Hailei Zhang
Co-authored papers 5
Bin Feng
The First Affiliated Hospital of Jinan University
Co-authored papers 4
Marcy E MacDonald
Co-authored papers 4
Michaela Bowden
Dana-Farber Cancer Institute
Co-authored papers 4
Cameron Brennan
Co-authored papers 4
Adam J Bass
Co-authored papers 4
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Co-authored papers 3
Eric P Winer
Dana-Farber Cancer Institute
Co-authored papers 3
Samuel S Freeman
St Vincent's Hospital Melbourne
Co-authored papers 3
Jennifer A Wargo
Co-authored papers 3
Maria Kost-Alimova
Co-authored papers 3
Keren Yizhak
Co-authored papers 3
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 3
Anat Stemmer-Rachamimov
Massachusetts General Hospital
Co-authored papers 3
James F Gusella
Co-authored papers 3
Sara M Tolaney
Dana-Farber Cancer Institute
Co-authored papers 3
Nir Hacohen
Broad Institute of MIT and Harvard
Co-authored papers 3
Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 3
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 3
Matthew Meyerson
Broad Institute
Co-authored papers 2
David R Ziehr
Brigham and Women's Hospital
Co-authored papers 2
Release 1.2